Patient Counselling (Community Pharmacy | Ch-5): D Pharma 2nd year Notes

Patient counselling is where everything covered so far in Community Pharmacy and Management comes together — the professional responsibilities, the prescription handling, and the communication skills — all applied directly to helping a patient use their medication safely and effectively. This chapter covers the definition and benefits of patient counselling, its three stages, common barriers and how to overcome them, counselling points for six major chronic diseases, and the role of Patient Package Inserts (PPI) and Patient Information Leaflets (PIL).

---

What is Patient Counselling?

Patient counselling is defined as the process of providing information, advice, and assistance to help patients use their medications correctly. Counselling patients about their medications is one of the most important responsibilities of a pharmacist, and pharmacists are often the only healthcare providers who focus specifically on medication education — covering how to take it, what to expect, potential side effects, and possible drug interactions.

Many pharmacists are trained to follow a counselling method developed by the Indian Health Service (IHS), which structures the counselling conversation into clear, repeatable steps.

---

Benefits of Patient Counselling

• Pharmacists are able to provide patients with effective, personalized information about their medication.
• Pharmacists carry significant responsibility in counselling patients managing chronic illness, where long-term adherence matters most.
• It helps prevent drug interactions and adverse drug reactions before they occur.
• It builds a therapeutic alliance between the pharmacist and patient, working toward mutually understood treatment goals.
• It turns the patient into an informed, active participant in their own disease management and self-care, rather than a passive recipient of medication.
• It positions the pharmacist as a healthcare professional offering genuine pharmaceutical care, not just dispensing medicines.

---

Stages of Patient Counselling

Stage 1: Introduction

• Introduce yourself to the patient.
• Review the patient’s medication record before the conversation begins.
• Explain the purpose and importance of the counselling session.
• Obtain a medication history interview, including details like allergies and previous incidents.
• Gather drug-related information such as allergies and use of herbal products.
• Assess the patient’s understanding of why they are receiving the therapy.
• Identify any actual or potential concerns important to the patient.

Stage 2: Present Patient Condition

This stage involves two types of assessment:

Personal assessment:

• Patient’s name and age.
• The patient’s mental ability to understand important information, such as black box warnings.
• Sensory and physical status.
• Cognitive abilities.
• The patient’s willingness to use the medication as prescribed.

Clinical assessment:

• How the patient is meant to use the medication.
• The patient’s attitude toward the medication.
• Possible barriers to adherence.
• Risk of patient non-adherence.
• The patient’s overall willingness to follow the treatment plan.

Stage 3: Closing the Counselling Session

• Verify the patient’s understanding by asking for feedback.
• Summarize the conversation by emphasizing the key points discussed.
• Give the patient an opportunity to raise any remaining concerns.
• Help the patient plan any necessary follow-up.

---

Barriers to Effective Counselling

Effective patient counselling in a community pharmacy setting is genuinely difficult, and barriers typically fall into three categories.

1. Pharmacist-Related Barriers

• Lack of knowledge about the patient.
• Lack of knowledge about the patient’s disease condition.
• Lack of confidence or counselling skill.
• The pharmacist’s own attitudes and beliefs.
• Age difference between pharmacist and patient.
• Religious difference between pharmacist and patient.

2. Patient-Related Barriers

• Lack of trust in the pharmacist.
• Lack of awareness of non-verbal communication cues.
• Cultural or religious beliefs that affect openness.
• Poor listening on the patient’s part.
• Lack of time available for the conversation.
• Information overload during the session.
• Physical or mental status of the patient.
• Emotional state of the patient.

3. System-Related Barriers

• Insufficient number of pharmacists in the pharmacy.
• Lack of time during busy hours.
• Pharmacist not having access to the patient’s full medication history.
• Poor communication between pharmacists and physicians.

Strategies to Overcome These Barriers

• Using positive body language throughout the conversation.
• Motivating the patient (receiver) to engage in the conversation.
• Checking whether it is a good time and place to speak with the patient.
• Being clear and using language the patient can understand.
• Communicating one piece of information at a time, rather than overwhelming the patient.
• Respecting a patient’s wish not to communicate if they’re unwilling at that moment.
• Confirming that the patient has correctly understood what was said.
• Choosing a location free of distractions for the conversation.
• Acknowledging any emotional response the patient shows to what’s being discussed.

---

Patient Counselling Points for Chronic Diseases

Hypertension

Hypertension is a clinical condition marked by elevated blood pressure in the blood vessels, which can lead to hemorrhagic and other related complications. Counselling for hypertension is managed through both pharmacological and non-pharmacological approaches.

Diabetes

Diabetes mellitus is a group of metabolic disorders that share hyperglycemia as a common feature, resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia can cause secondary damage to multiple organ systems, particularly the kidneys, eyes, nerves, and blood vessels.

• Pharmacological management: Biphasic insulin, teneligliptin, albiglutide, metformin, voglibose, and bromocriptine.
• Non-pharmacological management: Maintaining a proper diet plan since sugar level control is the primary management goal; avoiding any type of injury; keeping food and water readily available since increased hunger and thirst are common; regular exercise and yoga to support metabolism (BMR) and glucose control; and avoiding stress and depression by spending time in calming environments.

Asthma

Asthma is a condition in which the airways narrow, become swollen, and produce excess mucus, making breathing difficult and triggering coughing, wheezing, and shortness of breath.

• Pharmacological management: Salbutamol, salmeterol, ipratropium, glycopyrronium bromide, and combination therapy (such as albuterol with ipratropium).
• Non-pharmacological management: Avoiding known allergens; avoiding smoking, drinking, and chewing tobacco and other risk factors; regular use of supportive home remedies; practicing pranayama, yoga, and exercise to improve lung capacity; and following a government-regulated diet plan where required.

Tuberculosis

Tuberculosis is a potentially fatal, contagious disease that mainly affects the lungs through the formation of tubercles or granulomas, caused by Mycobacterium tuberculosis.

• Pharmacological management: Rifampicin, pyrazinamide, isoniazid, streptomycin, and ethambutol, sometimes alongside bronchodilators like salbutamol or salmeterol depending on the patient’s respiratory symptoms.
• Non-pharmacological management: Avoiding known allergens; avoiding smoking, drinking, and chewing tobacco; using supportive home remedies; practicing yoga and breathing exercises to support lung health; and following a structured diet plan as needed.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a multifactorial condition with a wide range of clinical manifestations and is a leading global cause of morbidity and mortality. It is characterized by progressive, partially reversible airflow obstruction, lung hyperinflation, and significant extrapulmonary complications.

• Pharmacological management: Salbutamol, salmeterol, ipratropium, glycopyrronium bromide, and combination therapy such as albuterol with ipratropium.
• Non-pharmacological management: Avoiding allergens; avoiding smoking and other risk-increasing habits; using supportive home remedies; practicing yoga and breathing exercises; and following an appropriate diet plan.

AIDS

HIV (Human Immunodeficiency Virus) causes Acquired Immune Deficiency Syndrome (AIDS) by destroying or impairing immune system cells, progressively reducing the body’s ability to fight disease.

• Pharmacological management: Lamivudine, zidovudine, indinavir, efavirenz, nevirapine, stavudine, ritonavir, and abacavir, often used in combination depending on the patient’s condition.
• Non-pharmacological management: Avoiding the reuse of needles and equipment; maintaining a proper, nutritious diet; practicing regular exercise, yoga, and meditation; using contraceptive methods (condoms) to reduce transmission risk; avoiding harmful habits like smoking and alcohol; and consulting a doctor or registered medical practitioner regularly and following their guidance.

---

Patient Package Inserts (PPI)

A Patient Package Insert (or medication guide) is a document provided alongside a prescription medication to give the patient additional information about that drug. This concept has been in practice in the United States since 1968 (known as the “Patient Package Insert”) and in the European Union (known as “Patient Information Leaflets”).

The document is written in non-technical language and covers what the drug is, how it should be used, how it works, and any safety concerns or precautions necessary while taking it. The underlying goal is to improve therapeutic outcomes by improving patient compliance and reducing errors from medication misuse.

Importance and Benefits

• Improves patient knowledge about their medicines and shapes a more accurate subjective sense of benefit versus risk.
• Provides information necessary for the safe and effective use of the drug.
• Supplies essential drug information for patients taking both over-the-counter and prescription-only medications.
• Increases patient awareness of medication-related issues, supports correct and safe use, and contributes to the overall success of the treatment plan.

Scenarios of PPI Use in India and Other Countries

The primary source of drug information is the package insert (PI) — a printed leaflet containing regulatory-guided information for the safe and effective use of a drug. It is also referred to as the prescription drug label or prescribing information. A good PI contains accurate, approved, and essential information, written in language that is non-promotional and not false or misleading.

In India, the regulatory authority overseeing this is the Ministry of Health and Family Welfare, Government of India. Pharmaceutical companies are required to submit full prescribing information as part of their new drug application, in line with Section 6.2 and 6.3 of Schedule D under the 1940 Act. Once the application is approved, this information accompanies the drug in its package.

Internationally, regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) periodically amend their regulations governing the content and format of drug labeling.

---

Patient Information Leaflets (PIL)

A Patient Information Leaflet is a technical document included in every medicine package to provide written information about the medication. Alternatively, it can be defined as a leaflet containing specific information about medical conditions, dosages, and side effects, packed with the medicine to inform the user about the product.

Uses

Patient Medication Information Leaflets (PMILs) serve as an important information source for patients. However, it’s worth noting that there is limited research on whether patients actually read PMILs regularly, what their opinions of them are, and how satisfied they are with the current format — an area that continues to be studied in pharmaceutical literature.

Exam Tips

• The three stages of patient counselling (Introduction, Present Patient Condition, Closing) are a guaranteed long-answer question — memorize the specific sub-points under each stage, especially the personal vs. clinical assessment split in Stage 2.
• The three categories of barriers (pharmacist-related, patient-related, system-related) are commonly asked as a classification question — be ready to list at least 3-4 examples under each category.
• For chronic disease counselling, examiners often ask for pharmacological + non-pharmacological management of a specific disease (e.g., “Write counselling points for a diabetic patient”) — memorize each disease’s drug list and lifestyle points as a standalone unit, since questions rarely ask for all six together.
• Note the drug overlap across asthma, TB, and COPD (salbutamol, salmeterol, ipratropium combinations appear in all three) — this is a useful memory shortcut, but don’t confuse it with each disease’s distinct first-line pharmacological agents (e.g., rifampicin/isoniazid are TB-specific, not used in asthma/COPD).
• PPI vs. PIL is a frequently confused pair — remember PPI originated in the US (1968) and EU, while PIL is the more general/technical term for the leaflet packed with the medicine. A “differentiate PPI and PIL” question is common.
• For India-specific regulatory questions, remember: Ministry of Health and Family Welfare is the regulatory authority, and PI submission falls under Schedule D, Section 6.2 and 6.3 of the 1940 Act — these exact references are high-value exam details.

FAQ – Patient counselling in community pharmacy